Difference between revisions of "Team:CSU CHINA/Composite Part"
| Line 6: | Line 6: | ||
<div class="clear"></div> | <div class="clear"></div> | ||
| − | + | <center> | |
<h1>Composite Parts</h1> | <h1>Composite Parts</h1> | ||
| + | </center> | ||
| + | <hr> | ||
<div class="block main-text main-text" > | <div class="block main-text main-text" > | ||
| Line 15: | Line 17: | ||
</p> | </p> | ||
<br/> | <br/> | ||
| − | < | + | <center> |
<img width="400" depth="400" src="https://static.igem.org/mediawiki/2018/e/e1/T--CSU_CHINA--PARTS2.png" /> | <img width="400" depth="400" src="https://static.igem.org/mediawiki/2018/e/e1/T--CSU_CHINA--PARTS2.png" /> | ||
| − | < | + | </center> |
| − | + | ||
<p> | <p> | ||
Promoter CMV can motivate the expression of GAL4-VP16 infusion protein which drives the expression of HSV-thymidine kinase (HSV-TK) to achieve the tumor killing effect as gene therapy. | Promoter CMV can motivate the expression of GAL4-VP16 infusion protein which drives the expression of HSV-thymidine kinase (HSV-TK) to achieve the tumor killing effect as gene therapy. | ||
</p> | </p> | ||
| − | < | + | <center> |
| − | + | ||
<img src="https://static.igem.org/mediawiki/2018/a/a2/T--CSU_CHINA--PARTS1.png" /> | <img src="https://static.igem.org/mediawiki/2018/a/a2/T--CSU_CHINA--PARTS1.png" /> | ||
| − | + | </center> | |
<br/> | <br/> | ||
<br/> | <br/> | ||
Latest revision as of 02:39, 18 October 2018
Composite Parts
We contributed to the Registry with one supportive part, ready to use in regulating expressions of other proteins . Function of the part was experimentally validated.
Promoter CMV can motivate the expression of GAL4-VP16 infusion protein which drives the expression of HSV-thymidine kinase (HSV-TK) to achieve the tumor killing effect as gene therapy.
